

3 510(k) Summary of Safety and Effectiveness

Date Summary Prepared	April 22, 2011
Manufacturer/Distributor/Sponsor	Arthrex, Inc. 1370 Creekside Boulevard Naples, FL 34108-1945 USA
510(k) Contact	Courtney Smith Regulatory Affairs Project Manager Arthrex, Inc. 1370 Creekside Boulevard Naples, FL 34108-1945 USA Telephone: 239/643.5553, ext. 1720 Fax: 239/598.5508 Email: courtney.smith@arthrex.com
Trade Name	<i>Distal Extremity Plate System</i>
Common Name	Plate, fixation, bone Screw, fixation, bone
Product Code -Classification Name CFR	HWC, HRS 21 CFR 888.3030: Single/multiple component metallic bone fixation appliances and accessories. 21 CFR 888.3040: Smooth or threaded metallic bone fixation fastener.
Predicate Device	<i>K090692</i> : Wright Ortholoc 2.0/2.4 Plate System <i>K063049</i> : Synthes Modular Mini Fragment LCP System <i>K050110</i> : Synthes Modular Foot System <i>K103705</i> : Arthrex Low Profile Screws
Purpose of Submission	This traditional 510(k) premarket notification is submitted to obtain clearance for the Distal Extremity Plate System.
Device Description and Intended Use	The Arthrex <i>Distal Extremity Plate System</i> is comprised of a variety of flat and pre-contoured plate geometries. The plates are manufactured from titanium and feature both locking and non-locking holes. The screw ranges from 2.0 mm to 4.0 mm in diameter and in length from 8 mm to 80 mm. The screws are solid and may be either locking or non-locking. The <i>Arthrex Distal Extremity Plate System</i> is intended for use in stabilization of fresh fractures, revision procedures, osteotomies, joint fusion and reconstruction of small bones and bone fragments of the hand/wrist, foot/ankle, and osteopenic bone.
Substantial Equivalence	The <i>Distal Extremity Plate System</i> is substantially equivalent

Summary

to the predicate devices, in which the basic features and intended uses are the same. Any differences between the *Distal Extremity Plate System* and the predicates are considered minor and do not raise questions concerning safety and effectiveness.

The proposed devices are composed of titanium that is substantially equivalent to the predicate devices.

The submitted mechanical testing data demonstrated that the bending strength of the plates and the torque and pull-out force of the screws are substantially equivalent to that of the predicate devices.

Based on the indication for use, technological characteristics, and the comparison to the predicate devices, Arthrex, Inc. has determined that the *Distal Extremity Plate System* is substantially equivalent to currently marketed predicate devices.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

Arthrex, Inc.
% Ms. Courtney Smith
Regulatory Affairs Project Manager
1370 Creekside Blvd.
Naples, FL 34108-1945

AUG - 2 2011

Re: K111253

Trade/Device Name: Arthrex Distal Extremity Plate System
Regulation Number: 888.3030
Regulation Name: Single/multiple component metallic bone fixation appliances and accessories
Regulatory Class: Class II
Product Code: HRS, HWC
Dated: May 2, 2011
Received: May 4, 2011

Dear Ms. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical


Page 2 – Ms. Courtney Smith

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson". The signature is fluid and cursive, with a long horizontal stroke at the end.

Mark N. Melkerson
Director
Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

2 Indications for Use Form

Indications for Use

510(k) Number (if known): K111253 (pg 1/1)

Device Name: *Arthrex Distal Extremity Plate System*

Indications For Use:


The *Arthrex Distal Extremity Plate System* is intended for use in stabilization of fresh fractures, revision procedures, osteotomies, joint fusion and reconstruction of small bones and bone fragments of the hand/wrist, foot/ankle, and osteopenic bone.

Prescription Use AND/OR Over-The-Counter Use
(Per 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

PAGE 1 of 1



(Division Sign-Off)
Division of Surgical, Orthopedic,
and Restorative Devices

510(k) Number K111253